Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: A cost-effectiveness analysis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 119, Issue 2, 2012, Pages 177-186

  Yamamoto, N ^a   Mori, R ^a   Jacklin, P ^b   Osuga, Y ^a   Kawana, K ^a   Shibuya, K ^a   Taketani, Y ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b National Collaborating Centre for Women's and Children's Health   (United Kingdom)

Author keywords

Cost effectiveness analysis; economics; human papillomavirus; vaccines

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEATH; DRUG COST; FEMALE; HUMAN; NONHUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCALE UP; SCHOOL CHILD; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

CHILD; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; JAPAN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 83655192027     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.2011.03036.x     Document Type: Article

References (47)

1. World Health Organization. The global burden of disease 2004 update. 2008. []. Last accessed 10 September 2010.
2. Center for Cancer Control and Information Services. Statistics. Tokyo, Japan: Center for cancer control and information services, 2010. (). Last accessed 10 September 2010.
3. Sherman ME, Wang SS, Carreon J, Devesa SS,. Mortality trends for cervical squamous and adenocarcinoma in the United States. Cancer 2005; 103: 1258-64. (Pubitemid 40328098)
4. Cancer Research UK. Cervical Cancer - UK Mortality Statistics. London, UK: Cancer Research UK, 2010. (). Last accessed 25 December 2010.
5. Ministry of Health, Labour and Welfare. Guideline for Health Education of Cancer Prevention and Implementation of Cancer Screening. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2008. (). Last accessed 10 September 2010.
6. Ministry of Health, Labour and Welfare. Business Report of Regional Healthcare and Healthcare of the Aged, Overview. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2008. (). Last accessed 10 September 2010.
7. Castellsague X, de Sanjose S, Aguado T, Louie KS, Bruni L, Munoz J, et al., HPV and Cervical Cancer in the World: 2007 Report Countries. Vaccine 2007; 25 (Suppl 3): C27-219.
8. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al., Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001; 286: 3106-14. (Pubitemid 34016525)
9. Matsumoto K, Yoshikawa H,. HPV vaccination and screening for cervical cancer. Clin Gynecol Obstet 2009; 63: 1140-7.
10. Armstrong EP,. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. JMCP 2010; 16: 217-30.
11. Dasbach E, Insinga R, Elbasha E,. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG 2008; 115: 947-56. (Pubitemid 351841762)
12. ® in italy. Vaccine 2010; 28: 3379-84.
13. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S,. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
14. Miura S, Matsumoto K, Oki A, Satoh T, Tsunoda H, Yasugi T, et al., Do we need a different strategy for HPV screening and vaccination in east asia? Int J Cancer 2006; 119: 2713-5. (Pubitemid 44691332)
15. Kawana K,. New strategies for cervical cancer prevention. Public Health 2009; 73: 886-93.
16. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N,. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer 2010; 20: 385-392.
17. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert J, Salomon J, O'Shea M, et al., Cost-effectiveness of HPV 16, 18 vaccination in brazil. Vaccine 2007; 25: 6257-70. (Pubitemid 47088030)
18. Surveillance Epidemiology and End Results (SEER). SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. (). Last accessed 10 December 2010.
19. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J,. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: NIH Publications, 2007.
20. Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T, et al., Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 2009; 100: 1312-6.
21. La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W,. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007; 25: 8352-8. (Pubitemid 350137594)
22. Rambout L, Hopkins L, Hutton B, Fergusson D,. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Can Med Assoc J 2007; 177: 469-79. (Pubitemid 47359770)
23. Schiffman M, Castle PE,. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003; 127: 930-4. (Pubitemid 36994850)
24. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al., Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
25. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al., Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
26. Yoshida Y, Sato S, Okamura C, Nishino Y, Yajima A,. Evaluating the accuracy of uterine cancer screening with the regional cancer registration system. Acta Cytol 2001; 45: 157-62. (Pubitemid 32234898)
27. Ministry of Health, Labour and Welfare. Vital statistics Japan 2008. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2009. (). Last accessed 10 September 2010.
28. Matsuda T, Ajiki K, Marugame T, Ioka A, Tsukuma H, Sobue T, et al., Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 2011; 41: 40-51.
29. Insinga R, Dasbach E, Elbasha E,. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009; 9: 119.
30. Goldhaber-Fiebert J, Stout N, Ortendahl J, Kuntz K, Goldie S, Salomon J,. Modeling human papillomavirus and cervical cancer in the united states for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11.
31. Igakutsushinsha. Quick Reference Matrix for Medical Service Score. Tokyo, Japan: Igakutsushinsha, 2009.
32. Ministry of Health, Labour and Welfare. The Result of Wage Structure Key Statistical Survey for 2008, Overview. Tokyo, Japan: Ministry of Health, Labour and Welfare, 2009. (). Last accessed 10 September 2010.
33. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al., Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-15. (Pubitemid 38584984)
34. Kulasingam SL, Myers ER,. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-9. (Pubitemid 37432955)
35. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y, et al., Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372-81. (Pubitemid 34493200)
36. Ministry of Economy, Trade and Industry. Economic Society Evaluation Guideline for Medical Equipment. Tokyo, Japan: Ministry of Economy, Trade and Industry, 2007. (). Last accessed 10 September 2010.
37. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL,. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford, UK: Oxford University Press, 2005.
38. Eichler H, Kong SX, Gerth WC, Mavros P, Jönsson B,. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28. (Pubitemid 39390832)
39. Ministry of Health Labour and Welfare. Readjustment of Examination of Breast Cancer and Uterine Cancer Based on Elderly Health Services. Tokyo, Japan: Ministry of Health Labour and Welfare, 2004. (). Last accessed 10 September 2010.
40. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al., Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28: 6247-55.
41. Matsuura Y, Kawagoe T, Toki N, Hachisuga T, Kashimura M,. Uterine cervical cancer screening in Japan: today and future. J UOEH 2009; 31: 181-93.
42. Research group to protect women from cervical cancer. Report of Research on the Cervical Cancer Screening. Japan: Research group to protect women from cervical cancer, 2008. (). Last accessed 22 December 2010.
43. Kaku T, Hirata N, Shinkoda H, Noguchi Y, Kitahara E, Hirakawa T, et al., Influences on women health care after change and reduction of financial resources for cytological screening of cervical cancer in Fukuoka prefecture, Japan. Mem Kyushu U Sch Health Sci 2003; 1: 23-8.
44. Expert committee on cervical cancer control. Research on Usage Situation of Free Ticket for Cervical Cancer Screening by Municipality, Promotion of Cancer Detection of Women 2009. Tokyo, Japan: Expert committee on cervical cancer control, 2010. (.) Last accessed 22 December 2010.
45. Australian Government, Department of Health and Ageing. Immunize Australia Program, Human Papillomavirus (HPV). Canberra, Australia: Australian Government, Department of Health and Ageing, 2010. (). Last accessed 22 December 2010.
46. Department of Health (UK). Immunisations at Secondary School: Your Questions Answered About the HPV and Td/IPV Vaccinations Given Between 12 and 18 years of Age. London, UK: Department of Health, 2010. (). Last accessed 22 December 2010.
47. Jit M, Choi YH, Edmunds WJ,. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337:a769.